ECSP077281A - Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos - Google Patents

Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos

Info

Publication number
ECSP077281A
ECSP077281A EC2007007281A ECSP077281A ECSP077281A EC SP077281 A ECSP077281 A EC SP077281A EC 2007007281 A EC2007007281 A EC 2007007281A EC SP077281 A ECSP077281 A EC SP077281A EC SP077281 A ECSP077281 A EC SP077281A
Authority
EC
Ecuador
Prior art keywords
growth hormone
human growth
glicerol
ramified
conjugates
Prior art date
Application number
EC2007007281A
Other languages
English (en)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of ECSP077281A publication Critical patent/ECSP077281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la PEGlilación de la hormona del crecimiento humano (hGh) usando un PEG ramificado con glicerol. La presente invención también se refiere a procesos para la PEGilación de hGH. Además, la presente invención se refiere a composiciones farmacéuticos que comprenden la hGH PEGilada. Otra realización es el uso de hGH PEGilada para el tratamiento de trastornos del crecimiento y del desarrollo.
EC2007007281A 2004-08-31 2007-02-27 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos ECSP077281A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
ECSP077281A true ECSP077281A (es) 2007-03-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007281A ECSP077281A (es) 2004-08-31 2007-02-27 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos

Country Status (24)

Country Link
EP (1) EP1789092A2 (es)
JP (1) JP2008511610A (es)
KR (1) KR20070042567A (es)
CN (1) CN101010105A (es)
AP (1) AP2007003919A0 (es)
AR (1) AR050851A1 (es)
AU (1) AU2005278903A1 (es)
BR (1) BRPI0515118A (es)
CA (1) CA2577999A1 (es)
CR (1) CR8942A (es)
EA (1) EA200700380A1 (es)
EC (1) ECSP077281A (es)
GT (1) GT200500235A (es)
IL (1) IL181085A0 (es)
MA (1) MA28908B1 (es)
MX (1) MX2007002441A (es)
NL (1) NL1029828C2 (es)
NO (1) NO20071322L (es)
PE (1) PE20060654A1 (es)
TN (1) TNSN07078A1 (es)
TW (1) TW200621291A (es)
UY (1) UY29088A1 (es)
WO (1) WO2006024953A2 (es)
ZA (1) ZA200701802B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RU2483081C2 (ru) * 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
MX2011001167A (es) 2008-07-31 2011-04-12 Pharmaessentia Corp Conjugados peptido-polimero.
SG195531A1 (en) * 2008-10-10 2013-12-30 Bionic Ear Inst Biodegradable polymer - bioactive moiety conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
SI2340271T1 (sl) 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CA2964390A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
ES2905105T3 (es) 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
EP3731871B1 (en) * 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
SI3731873T1 (sl) * 2017-12-29 2022-05-31 F. Hoffmann-La Roche Ag Postopek za zagotavljanje sestavka PEGiliranih beljakovin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
EP1546235B1 (en) * 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
WO2004060406A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
EP3593820A1 (en) * 2003-05-23 2020-01-15 Nektar Therapeutics Peg derivatives containing two peg chains

Also Published As

Publication number Publication date
NL1029828A1 (nl) 2006-03-01
BRPI0515118A (pt) 2008-07-01
PE20060654A1 (es) 2006-08-12
EP1789092A2 (en) 2007-05-30
TW200621291A (en) 2006-07-01
MA28908B1 (fr) 2007-10-01
UY29088A1 (es) 2006-03-31
WO2006024953A2 (en) 2006-03-09
AP2007003919A0 (en) 2007-02-28
MX2007002441A (es) 2007-05-04
AR050851A1 (es) 2006-11-29
AU2005278903A1 (en) 2006-03-09
CN101010105A (zh) 2007-08-01
IL181085A0 (en) 2007-07-04
JP2008511610A (ja) 2008-04-17
WO2006024953A3 (en) 2007-01-18
GT200500235A (es) 2006-03-21
CA2577999A1 (en) 2006-03-09
TNSN07078A1 (fr) 2008-06-02
KR20070042567A (ko) 2007-04-23
CR8942A (es) 2007-08-16
NL1029828C2 (nl) 2006-10-20
NO20071322L (no) 2007-05-29
ZA200701802B (en) 2008-08-27
EA200700380A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
ECSP077281A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos
AR047928A1 (es) Derivados de tetrahidropiridoindol
BR0313343A (pt) Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
BRPI0513508A (pt) conjugados de insulina-oligÈmero, formulações e usos desses
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
DK2249869T3 (da) Flydende formulering af FSH
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
EA201370006A1 (ru) Местная фармацевтическая композиция, содержащая флурбипрофен
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CL2012000261A1 (es) Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer.
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
DOP2005000172A (es) Conjugados de hormonas del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodo de uso de los mismos
BRPI0607844B8 (pt) uso do egf e ghrp-6
BR112022003751A2 (pt) Análogos de hemoglobina reticulada com tiosuccinila e métodos de uso e preparação dos mesmos
DK2058328T3 (da) Derivater af biologisk aktivt peptid VAPEEHPTLLTEAPLNPK